-
Stephan Moll, MD writes (last updated: Sept 9th, 2020)… Background: Hospitalized patients with COVID-19 are at increased risk for thrombosis – DVT, PE, and may be pulmonary micro-vascular thrombosis that possibly contributes to respiratory failure; arterial events appear to occur less commonly. Scientific/clinical data on prevalence of thrombosis, best prevention, and optimal therapy are limited.
-
Stephan Moll, MD writes… The CDC published an alert on Oct 26th, 2012, that they are investigating 12 cases of TTP (thrombotic thrombocytopenic purpura) in drug users who injected intravenously the opioid pain medication Opana ER® (oxymorphone extended-release), a medication made as a tablet and meant for oral use. The tablet was pulverized by the drug
-
Stephan Moll, MD writes… The more than 20 chapters and 801 pages of the respected 2012 ACCP Antithrombotic Therapy Guidelines – beautifully evidence-based, but always very cumbersome to read for the clinician looking for quick management guidance -, have now been summarized by the ACCP into a visually appealing, uncluttered, clinician-user-friendly document, referred to as
-
Beth Waldron, Program Director of Clot Connect, writes… The claim: “Eating lunch at your desk could increase your risk of DVT”—was the dramatic headline from UK’s Marie Claire magazine which caught my attention. (1) The online story went on to say that “Almost 75 per cent of office staff aged 21-30 who work 10-hour days
-
Following the diagnosis of deep vein thrombosis or pulmonary embolism, a patient may ask “When will my clot and pain go away?” An answer, written for patients, can be found on Clot Connect‘s patient education blog, here. This is the first in a series of posts designed to answer many of the most commonly asked
-
Stephan Moll, MD writes… Ischemic colitis is an uncommon and typically benign disorder. For mostly unclear reasons, multiple small vessels in the colonic wall have decreased perfusion or become occluded, resulting in patchy, superficially ulcerated areas. Typically, no surgical intervention is needed and the patient recovers spontaneously within 1-2 weeks. Often patients have only one episode. Few
-
Stephan Moll, MD writes…. The treatment of heparin induced thrombocytopenia may require the use of argatroban. Here is the argatroban nomogram used at our institution, the University of North Carolina (UNC) at Chapel Hill. Disclosure: I have no financial disclosures relevant to this post. Last updated: June 25th, 2013
-
Stephan Moll, MD writes… Klippel-Trenaunay Syndrome (KTS) is a rare congenital disorder of capillary, venous and lymphatic malformations and a localized disturbed growth of bone and/or soft tissue (see photographs)[ref 1]. Patients with KTS are at significantly increased risk for DVT, PE and superficial thrombophlebitis. KTS affects only one side of the body, typically the leg or the
-
Stephan Moll, MD writes… A clinically very relevant study (WARFASA) published today (May 24, 2012) in the New England Journal of Medicine [ref 1] shows that aspirin, 100 mg per day, reduces the risk of recurrent venous thromboembolism (VTE) in patients with unprovoked (= idiopathic) VTE, who have completed 6 to 18 months of anticoagulant therapy, without
-
Stephan Moll, MD writes… Not every patient with DVT or PE needs the same type of physician. The best combination for a patient to have may be (a) a primary care provider, (b) a health care professional in a formal Warfarin Clinic and (c) a physician with special expertise in thrombosis, and a primary care provider, for a
-
Stephan Moll, MD writes… A discussion for patients of questions commonly asked after a DVT are discussed here, in Clot Connect’s patient blog, such as: How quickly can I expect improvement? How active can I be after a DVT or PE? When can I go back to doing sports? When is it safe to fly again
A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center
Clot Connect 